SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

INDOCO REMEDIES

BSE: 532612 28 Jun 2025
Healthcare
₹ 284.3
Indoco Remedies Ltd. specializes in Pharmaceuticals within the Healthcare sector.

INDOCO REMEDIES - Share Price & Details

Market Cap
₹2,589
High /Low
388.0 / 190.0
Stock P/E
NA
Book Value
₹120.0
Dividend Yield
0.53
ROCE
2.76
ROE
₹-0.86
Face Value
2.0
PEG Ratio
NA
EVEBITDA
₹22.7
Debt
754
CMP / FCF
-44.6
Debt to equity
₹0.68
NP Ann
-8.73
High price all time
530.0
Piotroski score
₹2.0
Graham Number
NA
No. Eq. Shares
9.22
Net CF
₹-0.41
Net profit
-8.73
Price to book value
2.35
Interest Coverage
₹0.85
Low price all time
13.9
Industry PE
33.8
Reserves
₹1,085
Free Cash Flow
₹-164

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
INDOCO REMEDIES LTD.3537.5-262.43472.5-2.842,589
IOL CHEMICALS & PHARMACEUTICAL5323.0316.25277.81.08253325.1
NOVARTIS INDIA LTD.NANANANA250624.8

Peer Comparison Chart


About INDOCO REMEDIES

Indoco Remedies Ltd., with Security Code 532612, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Has Indoco Remedies declared dividend?

(07 Jun 2025)
Indoco Remedies Ltd has declared a 75% dividend, amounting to ₹1.5 per share, with an ex-date of September 19, 2024. Despite the dividend, the company's...
Read more →

Indoco Remedies arm launches heart attack drug Ticagrelor filmcoated in UK

(05 Jun 2025)
Mumbai: Indoco Remedies has announced that its subsidiary company, Indoco Remedies UK Limited, has officially launched Ticagrelor...
Read more →

Indoco Remedies Ltd announces the first day launch of Ticagrelor filmcoated tablets through its subsidiary in the United Kingdom

(05 Jun 2025)
Indoco announced today that its subsidiary company, Indoco Remedies UK Limited, officially launched Ticagrelor film-coated tablets 90mg in...
Read more →

Indoco Remedies Posts ₹40.4 Crore Net Loss in Q4 FY25

(26 May 2025)
Indoco Remedies Ltd. posted a consolidated net loss of ₹40.4 crore for the quarter ended March 31, 2025, a sharp contrast from a net profit...
Read more →

Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP

(24 May 2025)
Indoco Remedies Ltd. announced the final approval of Allopurinol Tablets USP 200 mg through its Abbreviated New Drug Application (ANDA) for...
Read more →

Indoco Remedies secures USFDA approval for Allopurinol Tablets to lower high uric acid levels in blood

(24 May 2025)
Mumbai: Indoco Remedies Ltd. has announced the final approval of Allopurinol Tablets USP 200 mg through its Abbreviated New Drug Application...
Read more →